What happens if a CMML patient is first diagnosed with ITP?
Chronic myelomonocytic leukemia (CMML) is a blood cancer that sometimes first appears as a low platelet count (thrombocytopenia). This can lead to an initial misdiagnosis of immune thrombocytopenia (ITP), an autoimmune disorder where the immune system attacks platelets. In such cases, ITP treatments may provide only temporary platelet improvement while the CMML continues to worsen. Recognizing the true diagnosis early is important for proper management.
What the research says
A case report describes a patient whose first symptom was thrombocytopenia, leading to an initial diagnosis of ITP 3. After immunosuppressive treatment, the patient's platelets temporarily rose, but later white blood cells increased, monocyte levels rose, and bone marrow tests showed typical CMML mutations, confirming CMML 3. The patient's condition stabilized after treatment with decitabine, a chemotherapy drug 3. Another case report highlights that CMML can be associated with autoimmune complications, and a combination of azacytidine and ruxolitinib improved severe thrombocytopenia in a patient with CMML and myelofibrosis 1. Additionally, a clinical trial found that in advanced CMML, persistent high monocyte or white blood cell counts after treatment are linked to worse survival, emphasizing the need for effective control of the disease 2.
What to ask your doctor
- Could my low platelet count be a sign of CMML rather than ITP?
- Should I have a bone marrow biopsy and genetic testing to rule out CMML?
- If I have CMML, what treatments (like decitabine or azacytidine) might help stabilize my platelet levels?
- How often should my blood counts be monitored to detect changes that might suggest CMML?
- Are there any clinical trials for CMML that I might be eligible for?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.